ERBB2 and triple-negative breast carcinoma: The incidence of brain metastases depends on the breast cancer molecular subtype, with human epidermal growth factor receptor 2–positive (HER2-positive) and triple-negative breast cancers having rates of brain metastases as high as 50% (8, 9).